1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Immatics N.V.
  6. News
  7. Summary
    IMTX   NL0015285941

IMMATICS N.V.

(IMTX)
  Report
Delayed Nasdaq  -  04:00 2022-08-05 pm EDT
12.45 USD   -1.58%
06/30IMMATICS N : Corporate Presentation, June 2022
PU
06/14IMMATICS N : MINUTES OF THE ANNUAL GENERAL MEETING OF SHAREHOLDERS OF IMMATICS N.V - Form 6-K
PU
06/13Immatics US, Inc., Entered into A Collaboration Agreement with Celgene Switzerland LLC
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Immatics N : Corporate Presentation, June 2022

06/30/2022 | 07:13am EDT

Immatics Corporate Presentation

June 30, 2022

© Immatics. Not for further reproduction or distribution.

Forward-Looking Statements

This presentation ("Presentation") is provided by Immatics N.V. ("Immatics" or the "Company") for informational purposes only. The information contained herein does not purport to be all-inclusive and Immatics nor any of its affiliates nor any of its or their control persons, officers, directors, employees or representatives makes any representation or warranty, express or implied, as to the accuracy, completeness or reliability of the information contained in this Presentation. You should consult your own counsel and tax and financial advisors as to legal and related matters concerning the matters described herein, and, by accepting this presentation, you confirm that you are not relying upon the information contained herein to make any decision.

Forward-Looking Statements. Certain statements in this presentation may be considered forward-looking statements. Forward-looking statements generally relate to future events or the Company's future financial or operating performance. For example, statements concerning timing of data read-outs for product candidates, the clinical trial application for IMA204, IMA301, IMA401, the Company's focus on partnerships to advance its strategy, projections of future cash on hand and other metrics are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may", "should", "expect", "intend", "will", "estimate", "anticipate", "believe", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable Immatics and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors beyond management's control including general economic conditions and other risks, uncertainties and factors set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"). Nothing in this presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Company undertakes no duty to update these forward-looking statements.

No Offer or Solicitation. This communication is for informational purposes only and does not constitute, or form a part of, an offer to sell or the solicitation of an offer to sell or an offer to buy or the solicitation of an offer to buy any securities, and there shall be no sale of securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law.

Certain information contained in this Presentation relates to or is based on studies, publications, surveys and the Company's own internal estimates and research. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while the Company believes its internal research is reliable, such research has not been verified by any independent source. Clinical study results and associated biomarker studies presented within this presentation are by definition prior to completion of the clinical trial and a clinical study report and, are therefore, preliminary in nature and subject to further quality checks including customary source data verification. This meeting and any information communicated at this meeting are strictly confidential and should not be discussed outside your organization.

2

Building a Leading TCR Therapeutics Company

Two Clinical-Stage Modalities

Pipeline of TCR-T and TCR Bispecific product candidates in clinical & preclinical development

Clinical PoC for

Differentiated

Therapeutic

Strategic

Solid

Cell Therapy

Platforms

Opportunity

Partnerships

Cash Runway

Objective responses

Unique technologies

Potential for addressing

World-leading

To reach next

across multiple solid

to identify true

large patient populations

industry players

value inflections

tumors in early TCR-T

cancer targets

with high prevalence

with synergistic

points across our

clinical development

and right TCRs

targets in solid tumors

expertise

portfolio

Intro

3

Our TCR-based Approaches Leverage the Full Target Space beyond the Cancer Cell Surface

Intro

4

Two Distinct TCR-based Therapeutic Modalities in Clinical Development

Autologous TCR-T (ACTengine®)

TCR Bispecifics (TCER®)

  • Strong clinical activity in patients with high tumor burden1
  • Single dose2
  • Proprietary manufacturing process for enhanced potency of T cells
  • Specialized medical centers
  • Off-the-shelfbiologic for immediate treatment
  • Repeat dosing
  • All hospitals and out-patient, opportunity for larger patient reach
  • Favorable commercial characteristics

Differentiated positioning of ACTengine® vs. TCER® based on patient population, medical need and geographical reach

Intro

1 Interim dose escalation data from the IMA203 Phase 1a trial with an objective response rate of 50% (8/16) across several solid tumor indications; 2 Repeat dosing without re-manufacturing possible

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Immatics NV published this content on 30 June 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 June 2022 11:12:05 UTC.


© Publicnow 2022
All news about IMMATICS N.V.
06/30IMMATICS N : Corporate Presentation, June 2022
PU
06/14IMMATICS N : MINUTES OF THE ANNUAL GENERAL MEETING OF SHAREHOLDERS OF IMMATICS N.V - Form ..
PU
06/13Immatics US, Inc., Entered into A Collaboration Agreement with Celgene Switzerland LLC
CI
06/07Editas Medicine, Immatics Sign Cancer Treatment Research, Licensing Deal
MT
06/07IMMATICS N : and Editas Medicine Enter Strategic Research Collaboration and Licensing Agre..
PU
06/03SVB Securities Adjusts Immatics NV's Price Target to $26 from $25, Keeps Outperform Rat..
MT
06/02Immatics Swings to Profit in Q1 as Revenue Surged on Upfront License Payment
MT
06/02Immatics, Bristol-Myers Squibb Expand Collaboration to Develop Allogeneic Cell Therapy ..
MT
06/02IMMATICS N : and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta All..
PU
06/02IMMATICS N : Corporate Presentation, June 2022
PU
More news
Analyst Recommendations on IMMATICS N.V.
More recommendations
Financials (USD)
Sales 2022 172 M - -
Net income 2022 17,5 M - -
Net cash 2022 153 M - -
P/E ratio 2022 30,3x
Yield 2022 -
Capitalization 783 M 783 M -
EV / Sales 2022 3,67x
EV / Sales 2023 16,0x
Nbr of Employees 373
Free-Float 59,8%
Chart IMMATICS N.V.
Duration : Period :
Immatics N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IMMATICS N.V.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 12,45 $
Average target price 20,00 $
Spread / Average Target 60,6%
EPS Revisions
Managers and Directors
Harpreet Singh-Jasuja Chief Executive Officer, MD & Executive Director
Arnd Christ Chief Financial Officer
Peter Alan Chambré Chairman
Cedrik M. Britten Chief Medical Officer
Steffen Walter Chief Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
IMMATICS N.V.-7.37%783
GILEAD SCIENCES, INC.-15.87%76 626
VERTEX PHARMACEUTICALS31.16%73 868
REGENERON PHARMACEUTICALS, INC.-2.84%65 600
BIONTECH SE-28.97%44 499
WUXI APPTEC CO., LTD.-19.26%41 093